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Background/aim: MODY3 associated with HNF1A is the most common form of MODY and is clinically misdiagnosed as type 1
diabetes due to similar clinical symptoms. This study aimed to analyze the role of HNF1A-regulated miRNAs as a biomarker in the
diagnosis of MODY3.
Materials and methods: MIN6 cells were transfected with the HNF1A cDNA expression vector for overexpression or with siRNA
specific to HNF1A to silence its expression. The HNF1A-regulated miRNAs were determined by RNA-Seq of the total RNA extract.
Expressions of the candidate miRNAs in blood samples of MODY3, type 1 diabetes, and type 2 diabetes patients and in healthy subjects
were compared statistically by Mann–Whitney U tests.
Results: This study revealed the presence of 238 known HNF1A-regulated miRNAs in MIN6 cells. miR-129-1-3p, miR-200b-3p, and
miR-378a-5p were selected as candidate miRNAs. The expression level of miR-378a-5p significantly decreased in type 2 diabetes and
MODY3 patients, while miR-200b-3p expression was significantly decreased only in MODY3 patients.
Conclusion: Although further studies with larger numbers of patients are required, this study demonstrated that the expression levels
of miR-200b-3p and miR-378a-5p decrease in MODY3 patients and suggests that miR-200b-3p is an especially strong candidate to use
clinically for selecting suspected MODY3 patients.
Key words: Biomarker, diabetes, miRNA, MODY3, miR-200, miR-378

1. Introduction
Maturity-onset diabetes of the young (MODY) is an
inherited early-onset nonautoimmune form of diabetes.
MODY is a clinically heterogeneous disease with 13
different phenotypes regarding the onset of the disease,
the level of hyperglycemia, and the response to the
treatment. Although it is classified as a monogenic disease
with autosomal dominant inheritance, it is a genetically
heterogeneous disease that is currently associated with
13 different genes. Among the 13 different genetic
types, MODY3 associated with the hepatocyte nuclear
factor transcription factor 1 alpha (HNF1A) gene is the
most common form of MODY in adults with 30%–60%
prevalence among MODYs. Approximately 70% of
MODY3 patients develop this disease before age of 25. It is

associated with functional deficiency of HNF1A. HNF1A
is a protein with 631 amino acids containing amino
terminal dimerization, pseudo-POU and homeodomaincontaining DNA binding, and carboxyl terminal
transactivation domains. The HNF1A gene is localized on
chromosome 12q24.31, spanning a region of 120 kb with
10 exons (1). It is expressed in different tissues including
pancreatic islets, kidneys, intestines, and the liver. The
HNF1A gene is expressed late in embryonic development
of the pancreas, where it is confined to developing islet cells,
and in the mature pancreas (2–4). Studies with HNF1Aknockout transgenic mice have demonstrated reduced
beta cell numbers when the HNF1A gene is turned off (5)
and the development of impaired glucose-induced insulin
secretion associated with diabetes (6,7).
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Micro RNAs (miRNAs) are ~22-nucleotide noncoding
single-stranded ribonucleic acids that can play important
roles in posttranscriptional regulation of gene expression.
It is estimated that there are more than 2000 miRNAs in the
human genome (www.miRbase.org) and these miRNAs
regulate 30% of the human transcripts (8,9). Recent
studies have revealed that miRNAs have important roles
in pancreatic development and beta cell differentiation
as well as the development of diabetes, diabetic
complications, insulin expression, insulin secretion, and
insulin action (10–12). It has been shown that the serum
miRNA expression profile differs significantly in type 2
diabetes patients with diabetic retinopathy (13). It was
demonstrated that when HNF1A is mutated to have the
common human Pro29finsC-HNF1A frameshift mutation,
miR-103 and miR-224 were overexpressed (14).
We report here the identification of HNF1Aregulated miRNAs, which may play important roles in
the pathogenesis of MODY3, and we explore the use of
candidate miRNAs as a biomarker for the diagnosis of
MODY3.
2. Materials and methods
2.1. MIN6 cell culture
Pancreatic β-cell line mouse insulinoma 6 (MIN6)
cells derived from mouse pancreas (AddexBio, San
Diego, CA, USA) were cultured in complete Dulbecco’s
modified Eagle’s medium (DMEM) containing 25 mM
glucose (high glucose), 15% (v/v) fetal bovine serum, 1%
penicillin/streptomycin, 2 mM glutamine, and 100 mM
β-mercaptoethanol at 37 °C in 5% CO2.
2.2. Transfection of MIN6 cells for HNF1A overexpression
MIN6 cells were cultured in 6-well plates and transfected
with 1 µg of human HNF1A expression vector to
overexpress the HNF1A gene using Xtremegene Gene
HP transfection reagent (Ref.: 06366236001, Roche
Life Science, USA) as described in the manufacturer’s
protocol for 48 h. The expression vector expressing the
wild-type human HNF1A gene was kindly provided by
Dr Eiji Awasaki from the University of Nagasaki, Japan.
Transfection studies were performed in triplicates.
2.3. Transfecting MIN6 cells for HNF1A silencing
MIN6 cells cultured in 6-well plates were transfected with
Lipofectamine RNAimax Reagent HNF1A-specific siRNA
purchased to silence the expression of the HNF1A gene
(Cat. No.: 13778150, Thermo Fisher Scientific, USA).
Silencing experiments were performed in triplicates.
2.4. Total RNA isolation
Total RNA was isolated from the HNF1A expression vector
and HNF1A siRNA transfected cells using the mirVana
miRNA isolation kit (Ambion Thermo Fisher Scientific,
USA) according to the manufacturer’s protocol.

2.5. Confirming the overexpression and silencing of
HNF1A
In order to confirm the overexpression and silencing
of HNF1A in MIN6 cells, HNF1A gene expression was
assessed using quantitative real-time PCR (qRT-PCR)
based on the TaqMan probe system (Thermo Fisher
Scientific, USA). For qRT-PCR, cDNA was synthesized
from total RNA samples isolated from transfected cells
by using a Transcriptor First Strand cDNA Synthesis Kit
(Roche, Germany).
qRT-PCR reaction was performed using the FastStart
Essential DNA Probes Master and Real-Time Ready
Custom Single Assay (Roche Life Science, USA), while the
human HNF1A assay (ID: 112176) for HNF1A plasmid
and mouse HNF1A assay (ID: 316865) for internal
expression of HNF1A were used. Mouse GAPDH assays
(ID: 307884) were utilized for normalization.
The data were normalized to the endogenously
expressed GAPDH and relative expression was calculated
by ΔΔCt method (15). qRT-PCR experiments were run in
duplicate and P-values were calculated by Mann–Whitney
test. P < 0.05 was considered statistically significant.
2.6. Western blot analysis
To validate the HNF1A overexpression and silencing in
protein levels, western blot analysis was carried out using
the Bolt Welcome Pack + iBlot 2 System (Invitrogen,
USA). To detect HNF1A protein produced in transfected
cells, rabbit polyclonal HNF1A antibody was used (Santa
Cruz, USA). As an internal control, monoclonal β-actin
antibody was used (Cell Signaling, USA). For detection,
the Opti-4CN Detection Kit with goat antirabbit antibody
was used (Biorad, USA).
Western blot analysis was also performed for the MIN6
cells that were not transfected as a control. ImageJ software
was used to quantitate the band intensity in the blot. Each
band was measured twice.
2.7. Next-generation sequencing of total RNA samples
After verifying the overexpression and silencing of HNF1A
in MIN6 cells, total RNA samples isolated from transfected
cells were sent to BGI, South Korea, for miRNA sequencing
with the use of Illumina TruSeq technology.
2.8. In silico prediction of targets genes
The possible targets of the differentially expressed miRNAs
were predicted by using the miRanda (www.microrna.org/
microrna/home.do) and TargetScan (www.targetscan.
org) databases on 18 August 2017. Then the targets were
classified according to signaling pathways by using the
Panther classification system (http://pantherdb.org),
accessed on 22 August 2017.
2.9. Validation of miR-129-1-3p, miR-200b-3p, and
miR-378a-5p expression
In order to validate the miR-129-1-3p, miR-200b-3p, and
miR-378a-5p as HNF1A targets, their expression levels
were analyzed by qRT-PCR in HNF1A overexpressed and
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3. Results
3.1. Overexpression and silencing of the HNF1A gene in
MIN6 cells
Overexpression and silencing of the HNF1A gene in
transfected MIN6 cells were verified by qRT-PCR. As a
control, MIN6 cells not transfected were used to compare
the overexpression and silencing of the HNF1A gene.
Both human and mouse HNF1A levels were
significantly increased in the overexpression group but
decreased in the silencing group as compared with the
control group (Figure 1). The significant increase in
mouse HNF1A expression level is possibly due to the
transcription factor activity of HNF1A, which activates its
own expression in a positive feedback mechanism (16).
3.2. Western blot analysis of HNF1A in overexpressed
and silenced MIN6 cells
HNF1A overexpression and silencing in transfected MIN6
cells were also validated by western blot for protein levels.
HNF1A protein levels (67,325 kDa) were measured by
normalizing them to the housekeeping protein β-actin
(Figure 2). Protein densities on the membrane were
measured using ImageJ software to have quantitative
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Log 2 Fold Change
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Figure 1. Validation of the overexpression and siRNA induced
silencing of HNF1A gene in transfected MIN6 cells by qRT-PCR.
Control represents the expression in MIN6 cells not transfected.
*: Statistically significant.

Figure 2. Western blot analysis of HNF1A overexpression and
siRNA induced silencing in MIN6 cells. O, Overexpression; S,
silencing; C, control.

information about the expression levels of HNF1A.
The β-actin bands were also measured to normalize the
HNF1A (Figure 3). HNF1A was almost 2.75 times more
expressed and 75% less expressed in overexpressed and
silenced cells, respectively, compared to the control.
3.3. Identification of HNF1A-regulated miRNAs
miRNA sequencing of the RNA extracts from HNF1A
overexpressed or silenced cells revealed that 238 known
2.0
Relative HNF1A Expression

silenced MIN6 cells as described above. TaqMan probes were
purchased from Thermo Fisher Scientific: hsa-miR-1291-3p (AAGCCCUUACCCCAAAAAGUAU), hsa-miR200b-3p (UAAUACUGCCUGGUAAUGAUGA), and hsamiR-378a-5p (CUCCUGACUCCAGGUCCUGUGU)
2.10. Analysis of the role of miR-129-1-3p, miR-200b3p, and miR-378a-5p as biomarkers for the diagnosis of
MODY3 patients
The expression levels of miR-129-1-3p, miR-200b3p, and miR-378a-5p were compared in blood samples
of the study populations, which consisted of MODY3
patients (n = 4), type 1 diabetes (n=5), and type 2 diabetes
(n=5) patients and healthy controls (n = 3), which were
analyzed using miRNA-specific TaqMan probes (Thermo
Fisher Scientific, USA) with qRT-PCR as described above
and compared statistically using Mann–Whitney U tests.
Blood samples were collected in Paxgene Blood RNA
Tubes (Cat No.: 762165, BD Biosciences, Switzerland).
MODY3 patients, referred to our laboratory by the
Turkish Diabetes Foundation, were previously determined
by NGS analysis of the HNF1A gene by us (unpublished
data). Blood samples of type 1 and type 2 diabetes patients
were also provided by the Turkish Diabetes Foundation.
Control blood samples were obtained from individuals
without a familial diabetes history who were nonobese
and younger than 40 years old. The control subjects were
identified clinically as nondiabetic and without major
clinical risk factors for diabetes. Ethical approval for this
study was obtained from the ethical committee of İstanbul
Arel University.

**

1.5

1.0
**
0.5

0.0

Overexpression

Control

Silencing

Figure 3. Densitometric analysis of western blots of HNF1A
overexpression and siRNA induced silencing in MIN6 cells. O,
overexpression; S, silencing; C, control.
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miRNAs in the miRBase database that were predicted
by MIREAP and Mirdeep software have significant
differential expression (Supplementary Table S1).
In order to have more valid data, additional filtering
steps were applied to the miRNA sequencing analysis for
the known miRNAs. miRNAs having log2-fold change
lower than 1 were eliminated. After that, miRNAs that had
the most significant (P < 0.05) differential expression were
selected. miRNAs that passed through these filtering steps
are shown in Table 1.
In order to determine the potential targets of
differentially expressed miRNAs, database analysis was
performed using the miRanda and TargetScan target

prediction tools and classification of the targets with
Panther algorithms. In silico prediction of target signaling
pathways revealed that the insulin/IGF pathway, protein
kinase B signaling pathway, Wnt signaling pathway, and
glycolysis pathway are among the targets of miR-129-1-3p,
miR-200b-3p, and miR-378a-5p.
3.4. Analysis of the role of miR-129-1-3p, miR-200b3p, and miR-378a-5p as biomarkers for the diagnosis of
MODY3 patients
miR-129-1-3p, miR-200b-3p, and miR-378a-5p were
selected as candidate miRNAs to explore their roles as
biomarkers to diagnose MODY3.

Table 1. Fold change and P-values of known miRNAs having the most significant differential expression.
P-values smaller than 1e-350 are shown as 0.
Name

Log2 fold change
(overexpression/silencing)

P-value

miR-129-1-3p

2.63

0

miR-129-2-3p

2.87

0

Let-7b-3p

2.46

7.6e-15

miR-378a-5p

2.24

6.7e-30

miR-3072-3p

2.41

7.74e-37

miR-8112

1.91

4.48e-35

miR-200b-3p

1.02

7.34e-30

miR-324-5p

2.26

2.12e-26

miR-296-3p

2.50

7.33e-6

miR-1983

2.01

2.73e-3

3.0
Overexpression

Fold Change

2.5

Silencing

2.0
1.5
1.0
0.5
0.0

miR-129-1-3p

miR-200b-3p

miR-378a-5p

Figure 4. Validation analysis by qRT-PCR of the candidate
miRNAs in HNF1A overexpressed and silenced MIN6 cells.

Figure 5. Fold expression changes of the candidate miRNAs
in MODY3 patients, type 1 diabetes patients, type 2 diabetes
patients, and healthy subjects. Black bars: MODY3 patients (n =
4); light gray bars: type 1 diabetes patients (n = 5); dark gray bars,
type 2 diabetes patients (n = 5); white bars: control (n = 3).
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Validation analysis by qRT-PCR of the candidate
miRNAs in HNF1A overexpressed and silenced MIN6
cells revealed that their expression significantly decreased
with the silencing of the HNF1A gene (Figure 4).
The expression level of miR-129-1-3p was decreased in
MODY3 and type 2 diabetes patients by 0.8- and 0.7-fold,
respectively, and increased by 1.4-fold in type 1 diabetes
patients relative to the control group. However, statistical
analysis revealed that the decrease in its expression in
MODY3 and type 2 diabetes patients was not significantly
different (P > 0.05), as well as the increase in type 1 diabetes
patients (Figure 5).
qRT-PCR analysis of miR-200b-3p in the blood
samples of the study populations demonstrated that its
expression decreased significantly in MODY3 patients by
0.5-fold relative to the control (P = 0.011). In addition,
its expression level decreased in type 1 and type 2
diabetes patients compared to the control group, but not
significantly (P > 0.05) (Figure 5).
Expression analysis of miR-378a-5p in blood samples
revealed that its expression significantly decreased by 0.3fold in MODY3 patients compared to the control group
(P = 0.011). Comparing its expression in type 2 diabetes
patients with controls demonstrated that it was decreased
significantly by 0.5-fold (P = 0.045). Although its
expression increased in type 1 Diabetes patients by 1.28fold compared to the control group, the difference was not
significant (P > 0.05) (Figure 5).
4. Discussion
MODY3 associated with the HNF1A gene is the most
common form of MODY in adults with 30%–60%
prevalence among MODYs.
The HNF1A gene is expressed in the pancreas, liver,
and kidneys and encodes for the transcription factor
HNF1A. HNF1A regulates expression of the genes
involved in glucose metabolism, glucose transportation,
and the insulin gene as well as liver-specific genes. HNF4A,
for example, is regulated by HNF1A and is required for
the normal functioning of the liver and pancreas. It is
also a transcription factor that is in a positive feedback
mechanism with HNF1A to increase HNF1A expression
(16).
There are more than 300 different HNF1A gene
mutations in the human genome mutation database.
MODY3 exhibits variable clinical phenotypes. The clinical
phenotype of MODY3 can vary within the same family even
if the patients have the same mutation. Although MODY3
has been associated with HNF1A gene mutations, it
presents variable clinical phenotypes even within the same
family (17,18). The onset and prognosis of the disease can
vary depending on the location of the HNF1A mutation.
For example, in patients with mutations between exon 1
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and 6, the onset of the disease can be earlier than expected
(19,20).
Studies have demonstrated that in addition to the
obesity and other genetic loci, the MODY3 phenotype
depends on both mutation type and the location of the
mutation along the HNF1A gene. MODY3 is frequently
misdiagnosed as type 1 Diabetes due to the similar clinical
features and the early onset of diabetes. Correct diagnosis
of MODY3 is important for preventive treatment since
MODY3 patients are under higher risk of diabetic
complications such as heart attacks and strokes (21–23).
Correct diagnosis of MODY3 is possible by genetic
mutation testing. However, despite the cost-effectiveness
of direct DNA sequencing analysis, genetic mutation
testing is still an expensive and time-consuming process,
especially in developing countries.
It is important to determine the molecular mechanism
of diabetes, which is considered as an epidemic disease
due to increasing prevalence worldwide, to decrease its
morbidity and mortality rate. On the other hand, the exact
pathogenesis of diabetes has not been resolved yet. Recent
studies have revealed that miRNAs have important roles
in the development of diabetes, diabetic complications,
insulin expression, insulin secretion, and insulin action
(24). For example, miR-30d is implicated in insulin gene
transcription. Another study demonstrated that miR-103
and miR-224 are involved in MODY3 pathogenesis due to
HNF1A Pro29fsinsC mutation in INS-1 insulinoma cell
lines (12,14).
miR-375 in pancreatic beta cells has also been shown to
be involved in insulin secretion and pancreas development
(10,25), miR-133 in cardiac cells has been shown to be
involved in diabetic cardiac complications, and miR-192
in the kidneys has been shown to be involved in diabetic
nephropathy (26). It has been reported that miR-30d
regulates the expression of the MafA transcription factor,
which is a protein that inhibits the expression of insulin
(27).
In this study, we report the differential expression of
miRNAs by overexpression and silencing of the human
HNF1A gene in a heterologous cell system. The current
report has revealed differential expression of 238 known
miRNAs in the miRbase database. Among the 238
identified miRNAs, miR-129-1-3p, miR-129-2-3p, miR200b-3p, miR-296-3p, miR-378a-5p, miR-324-5p, let-7b3p, miR-3072-3p, miR-8112, and miR-1983 were the ones
having the most significant differential expression by the
change in HNF1A expression. miR-3072-3p, miR-8112,
and miR-1983 are not present in humans. miR-324-5p, on
the other hand, is conserved in both humans and mice.
The other 6 miRNAs have been associated with diabetes
and/or metabolic pathways related with diabetes in the
literature (28).
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In this study we also assessed the roles of miR-1291-3p, miR-200b-3p, and miR-378a-5p as biomarkers to
use in the diagnosis of MODY3 patients. miR-129 was
shown to exhibit a role in glucose metabolism in earlier
studies (29). miR-200b-3p was associated with diabetic
nephropathy by inhibiting the expression of FOG2 protein.
FOG2 blocks the function of Akt, which is a kinase that
induces cell growth. Inhibition of the FOG2 gene by miR200b prevents its blocking effect on Akt, which can lead to
an increase in cell volume in nephrons, therefore causing
diabetic nephropathy (30). miR-200b was also reported
to facilitate insulin signaling by blocking FOG2 (31).
Moreover, overexpression of miR-378a-5p was shown
to display hepatic insulin resistance by blocking insulin
signaling through targeting p110α, which is a critical
component of insulin signaling (32).
In silico prediction by miRanda and TargetScan of
the targets of the selected miRNAs revealed that target
genes such as SLC2A glucose transporter family genes,
G6PC, IDH2, GPI, and H6PD are involved in glucose
metabolism. Functional classification of the target genes
in signaling pathways by Panther also predicted target
genes in signaling pathways with glucose metabolism. This
observation together with literature data imply the role of
selected miRNAs in the pathogenesis of MODY3.
Although previous studies have analyzed miRNA
profiles and implicated miRNAs in beta cell development
and function as well as diabetes pathogenesis, the reflection
of these findings on clinical diagnosis has been very
limited. MODY has been considered as a rare disease that
constitutes 0.6% to 2% of diabetic cases. However, since
clinical diagnosis of diabetes has depended on high blood
glucose levels, clinical diagnosis of MODY is complicated

due to similar clinical symptoms as type 1 or type 2 diabetes.
It is estimated that 80% of MODY cases are misdiagnosed
as type 1 or type 2 diabetes (33). Accurate clinical diagnosis
of MODY is not only important for proper management of
the disease and but also for the reduction of the cost of
treatment. With the correct diagnosis, MODY3 is usually
treated with sulfonylurea with good results (34), without
insulin requirements. However, due to the complexity of
clinical diagnosis of MODY, its correct diagnosis is done
with genetic diagnosis, which is an expensive diagnosis
method. Therefore, availability of biomarkers is important
for the accurate diagnosis of MODY.
Earlier studies identified that miR-103 levels are
higher in MODY3 patients (12,35). Different from those
earlier studies, we observed that expression levels of the
selected miRNA molecules decreased in MODY patients
significantly, except miR-129-1-3p expression.
In conclusion, although further studies with larger
patient numbers are required, the results indicate that
miR-200b-3p and miR-378a-5p can be used as biomarkers,
which can be isolated from the peripheral blood of
suspected patients easily for the diagnosis of MODY3 by
selecting patients for HNF1A gene analysis. Our results
also indicate that miR-200b-3p is a strong candidate to
use for the diagnosis of MODY3 since the expression level
of miR-200b-3p was significantly different only between
MODY3 and the control group.
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Supplementary Table S1. Total list of the 238 known miRNAs differentially expressed between HNF1A silenced and HNF1A
overexpressed.
miRNA name

Normalized expression ratio

P-value

mmu-miR-182-5p

–0.452678799518914

0

mmu-miR-375-3p

0.0638994916997115

0

mmu-miR-741-3p

0.503751734925089

0

mmu-miR-26a-5p

–0.446979195534201

0

mmu-miR-30a-5p

–0.342905490622129

0

mmu-miR-92b-3p

1.19273995425598

0

mmu-miR-99b-5p

0.128683732567218

0

mmu-miR-871-3p

0.129122957214776

0

mmu-miR-434-3p

–0.436202236869665

0

mmu-let-7i-5p

–0.314178822996219

0

mmu-miR-486-5p

0.593818708608856

0

mmu-miR-3107-5p

0.593947138218431

0

mmu-miR-191-5p

–0.177765330389622

0

mmu-let-7a-5p

–0.299038288029997

0

mmu-miR-465a-3p

–0.307350533997947

0

mmu-miR-465b-3p

–0.307318587695004

0

mmu-miR-465c-3p

–0.306777581692746

0

mmu-miR-30c-5p

–0.672878120831967

0

mmu-miR-541-5p

–0.289046362504695

0

mmu-miR-25-3p

–0.358587008501848

0

mmu-miR-129-1-3p

–2.63315184314232

0

mmu-miR-129-2-3p

–2.87047488433413

0

mmu-miR-125a-5p

0.166280400854888

1.69367184355694e-307

mmu-let-7f-5p

–0.106958019665114

3.41919359686734e-266

mmu-miR-470-5p

0.0773382878742092

1.2132940393905e-261

mmu-miR-186-5p

–0.336644361877964

1.25649969747858e-255

mmu-miR-378a-3p

–0.392052811102228

5.53897457519369e-251

mmu-miR-383-5p

–0.621655718998431

3.03274212422102e-241

mmu-miR-148a-3p

–0.907434087186997

2.34042154570019e-220

mmu-miR-30e-5p

–0.269989896907313

1.03884237748353e-213

mmu-miR-30d-5p

–0.196892017106382

2.36177844278362e-211

mmu-miR-22-3p

–0.175677793518122

5.99320613489461e-210

mmu-miR-183-5p

–0.411619502280237

1.28670255035362e-197

mmu-miR-127-3p

–0.0773442183240006

1.38339877932726e-191

mmu-miR-301a-3p

–0.472333966474311

9.14039557470053e-188

mmu-miR-16-5p

–0.240039036278121

9.30816903185997e-184

mmu-miR-141-3p

–0.360265785086673

2.8185483718784e-182

mmu-miR-181a-5p

–0.1110951257089

1.01120647298737e-175

mmu-let-7d-3p

–1.05592176511066

3.51373503338084e-169

mmu-miR-340-5p

–0.194680063418996

2.52285952527764e-133

mmu-miR-879-5p

–1.77985973076281

1.7560185576325e-132
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mmu-miR-93-5p

–0.383108641137999

4.67404366029343e-130

mmu-miR-30b-5p

–0.514596520444986

3.41522222847916e-125

mmu-miR-540-3p

0.213066127950805

8.0608689018208e-112

mmu-miR-423-5p

0.184110878318908

2.37707931736613e-111

mmu-miR-27b-3p

–0.089153395670081

7.55345499809308e-105

mmu-miR-181b-5p

0.193469352700873

2.29864921051406e-94

mmu-miR-128-3p

–0.712680110427195

2.66037768821618e-87

mmu-miR-381-3p

–0.221494301024121

1.46990843746614e-85

mmu-miR-431-5p

–0.421256565833643

5.53935149391204e-81

mmu-miR-151-3p

–0.203491318752407

8.21940168086931e-79

mmu-miR-143-3p

0.832946151769782

2.94183883422432e-78

mmu-miR-871-5p

–0.173702877013673

5.35180268527553e-76

mmu-miR-410-3p

–0.26185346288818

1.22058961036415e-74

mmu-miR-465c-5p

–0.14404984059623

1.08546388865468e-71

mmu-miR-872-3p

–0.663269232833981

3.00852565107324e-69

mmu-miR-98-5p

–0.283838002703311

4.16655483549628e-63

mmu-miR-881-3p

0.104001345880619

7.62487412171674e-63

mmu-miR-129-5p

–0.457402695992581

2.95201029301016e-61

mmu-let-7d-5p

–0.222272125975005

9.08971349915732e-61

mmu-miR-100-5p

–1.54165000797003

1.42006042428435e-60

mmu-miR-21a-5p

–0.187692111945951

2.16585084386567e-60

mmu-miR-103-3p

–0.258205160526732

1.97988141926106e-59

mmu-let-7b-5p

0.255172399078458

3.18952868633616e-57

mmu-miR-411-5p

–0.114834089404816

4.15230000627799e-57

mmu-miR-708-3p

–0.712000059778614

1.68353210765087e-51

mmu-miR-30a-3p

–0.289476984628575

1.47420140287068e-48

mmu-miR-30e-3p

–0.221400026953764

4.75667654280608e-48

mmu-miR-106b-3p

–0.344235828666461

3.18904289886218e-46

mmu-miR-1306-5p

–1.88234625970102

1.31642151816964e-44

mmu-miR-15b-5p

–0.447445827582628

1.02297551236049e-42

mmu-miR-409-5p

–0.172135578166912

1.20063807210826e-42

mmu-miR-298-5p

–0.725793535932203

6.06553446238802e-42

mmu-miR-149-5p

–0.632374085625145

4.36470074325946e-41

mmu-miR-192-5p

–0.0770450559628058

4.84100984666721e-41

mmu-miR-342-3p

–0.428480182905717

1.72996132322848e-39

mmu-miR-10a-5p

–0.517509489316492

1.24240924727218e-38

mmu-let-7j

–0.341542514239013

4.7233528623878e-38

mmu-miR-3072-3p

–2.40589693205293

7.73752611907167e-37

mmu-miR-140-3p

–0.318012097399061

1.40826700374423e-35

mmu-miR-29a-3p

–0.228139504957045

3.17397737011653e-35

mmu-miR-8112

–1.91214406363521

4.47945845751826e-35

mmu-miR-484

–0.481051611489073

5.05953528505615e-35

mmu-miR-210-3p

–0.359030105960363

1.23408083849539e-33

mmu-miR-96-5p

–0.459936771765823

9.2531255408457e-33
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mmu-miR-339-5p

–1.41762596690786

4.42142599172791e-31

mmu-miR-200b-3p

–1.02156676865635

1.87645565293695e-30

mmu-miR-378a-5p

–2.2402468708092

6.70066742598742e-30

mmu-miR-132-3p

–0.672574625576539

7.18754695234039e-30

mmu-miR-320-3p

–0.305393111675315

1.23738841845537e-29

mmu-miR-421-3p

–0.281221132169808

3.48271266228367e-29

mmu-miR-301b-3p

–0.607388772979687

1.30969991306899e-28

mmu-miR-7a-2-3p

–1.0130972123952

1.24862924159265e-27

mmu-miR-299a-5p

–3.59669490927294

2.760957851923e-27

mmu-miR-324-5p

–2.25525913832853

2.11551828265749e-26

mmu-miR-465b-5p

–0.171275323320362

5.68692139685635e-26

mmu-miR-878-5p

–0.125897022274131

4.11155104460853e-25

mmu-miR-532-5p

–0.271621719311735

2.11018711331628e-24

mmu-miR-341-3p

–0.180022446988417

1.56419190420306e-23

mmu-miR-99a-5p

–0.382198518225657

2.92224023793802e-23

mmu-miR-463-5p

–0.174419055402014

3.18584666914473e-23

mmu-let-7g-5p

–0.13992274926532

3.64310887615647e-23

mmu-miR-126a-5p

–1.10736335943363

1.02568431015465e-22

mmu-miR-6240

–1.78186486665319

1.09339016184513e-22

mmu-miR-377-3p

–0.490119777262201

1.42999519694685e-22

mmu-miR-101a-3p

–0.155560272659514

2.55417988629989e-21

mmu-miR-1839-5p

–0.190566619148516

4.28748529365401e-21

mmu-miR-130a-3p

–0.165193506204693

1.01171012578178e-19

mmu-miR-667-3p

–0.596116570187529

1.38962478759473e-19

mmu-miR-666-5p

–0.359784693573664

2.02993631880947e-19

mmu-miR-136-3p

–0.158095000047297

3.73099515913075e-19

mmu-miR-483-3p

–0.903543423241437

5.50288786133603e-19

mmu-miR-107-3p

–0.250070597727832

6.63023931500389e-19

mmu-miR-344d-3p

–0.690451752922604

1.06627289781449e-18

mmu-miR-379-5p

–1.08975350827124

1.10197980323352e-18

mmu-miR-429-3p

–1.51202528291428

1.24175316642778e-18

mmu-miR-872-5p

–0.239668496007928

2.28786373469554e-18

mmu-miR-743b-3p

–0.0950620672250738

2.76606362542091e-18

mmu-miR-1249-3p

–2.71732461445847

2.54795730303489e-17

mmu-miR-138-5p

–0.301807575523933

4.41695521664073e-17

mmu-miR-1224-5p

–0.247593497063423

5.66875406314911e-17

mmu-miR-325-3p

–0.520740050828024

7.2183076805602e-17

mmu-miR-26b-5p

–0.195262715512335

2.52744460084795e-16

mmu-let-7a-1-3p

–1.1974571419592

3.04236721490505e-16

mmu-let-7c-2-3p

–1.1974571419592

3.04236721490505e-16

mmu-miR-8114

–1.12390714692677

3.31336659331168e-16

mmu-miR-488-5p

–0.54862577847145

5.7205059867273e-16

mmu-miR-666-3p

–0.550221897731884

7.18182638306043e-16

mmu-miR-425-5p

–0.405575685561501

9.69684392910438e-16
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mmu-miR-3473b

–2.14443494603789

1.21747667794163e-15

mmu-miR-532-3p

–1.34151627884515

2.87951373859775e-15

mmu-let-7b-3p

–2.45993677176582

7.60187136228245e-15

mmu-miR-184-3p

–0.0948310879899717

1.57449679839132e-14

mmu-miR-200a-3p

–0.836312650675562

3.4157364807605e-14

mmu-miR-378c

–0.503678235586845

3.46261746419981e-14

mmu-miR-369-3p

–0.553494877323201

3.68518195788117e-14

mmu-let-7e-5p

–0.0891740931317544

1.90005866848107e-13

mmu-miR-1983

–2.0057286752063

2.72608366275473e-13

mmu-miR-28a-3p

–0.519599693064162

6.75045649003154e-13

mmu-miR-488-3p

–0.426737428232236

6.82819372770724e-13

mmu-miR-376a-5p

–0.64521602008517

1.63642346437133e-12

mmu-miR-668-3p

–0.512166730538382

3.76772550083002e-12

mmu-miR-3473e

–1.92404487761259

4.80687205292867e-12

mmu-miR-152-3p

–1.13887542069599

5.93709174132294e-12

mmu-miR-574-3p

–1.34513229627502

1.3731431374927e-11

mmu-miR-671-3p

0.242760824510358

1.45684679609256e-11

mmu-miR-328-3p

–0.535180520060232

2.03160021860417e-11

mmu-miR-200c-3p

–0.60827491099999

3.91131029372369e-11

mmu-miR-3078-5p

–0.792561449784689

8.91815939517995e-11

mmu-miR-1981-3p

–1.17466714745731

1.07271617554489e-10

mmu-miR-195a-5p

–0.248629131524952

2.48559061599309e-10

mmu-miR-664-3p

–2.70786428520941

2.67133059147703e-10

mmu-miR-673-5p

–0.189257883184769

2.92314885347336e-10

mmu-miR-183-3p

–1.3264696297582

6.29088758601262e-10

mmu-miR-345-3p

–1.30793367832077

6.37364356559074e-10

mmu-miR-106b-5p

–0.32982463691053

6.88164173636534e-10

mmu-miR-7688-5p

–0.621196912081009

7.79061298825916e-10

mmu-miR-337-5p

–0.237613815968107

8.45754129472629e-10

mmu-miR-126a-3p

–1.60211678272523

1.16519207741709e-09

mmu-miR-199a-3p

–1.13453648497166

2.99119835025869e-09

mmu-miR-199b-3p

–1.13453648497166

2.99119835025869e-09

mmu-miR-329-5p

–0.535167362726721

3.92359590082409e-09

mmu-miR-880-3p

–0.311881844847498

4.71804188861858e-09

mmu-miR-877-5p

0.170847704951424

8.61640035364388e-09

mmu-miR-345-5p

–0.824877755613279

1.15504981638531e-08

mmu-miR-300-3p

–0.19814898559807

1.372577368356e-08

mmu-miR-136-5p

–0.175500320009298

1.78791245607475e-08

mmu-miR-1199-5p

–0.7303886491621

1.96084144860639e-08

mmu-miR-98-3p

–1.05356413361411

2.10251098978552e-08

mmu-miR-1982-3p

–3.54739961301616

3.27943639503821e-08

mmu-miR-540-5p

–1.23252627566275

4.92723687935195e-08

mmu-miR-325-5p

–0.563537013780181

6.75893723466598e-08

mmu-miR-700-5p

–0.921888382381636

8.11518690699869e-08
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mmu-miR-7082-3p

–5.74533899062807

8.92533013327541e-08

mmu-miR-743b-5p

–0.263079442536512

1.79292152569821e-07

mmu-miR-331-3p

–2.47116402718908

1.82348440720504e-07

mmu-miR-3068-3p

–0.621617779113228

2.59399108969261e-07

mmu-miR-199a-5p

–5.62986177320814

2.80562668333876e-07

mmu-miR-323-3p

–0.578331472568054

3.95517503037098e-07

mmu-miR-26b-3p

–0.517463948720172

4.1688706330009e-07

mmu-miR-361-3p

–0.381838991494902

6.22163655774215e-07

mmu-miR-153-5p

–0.600546206383581

7.94098778673029e-07

mmu-miR-431-3p

–0.321261209967765

1.23358607692966e-06

mmu-miR-674-3p

–0.495457488117086

1.24224775285115e-06

mmu-miR-487b-3p

–0.350044514848637

1.45903567763177e-06

mmu-miR-1843a-5p

–0.383585885635709

1.50837584983891e-06

mmu-miR-27a-3p

–0.385936190322045

1.65627878513038e-06

mmu-miR-362-3p

–0.786831119546535

2.31562068576395e-06

mmu-miR-574-5p

–0.937984068570467

2.48124993636522e-06

mmu-miR-370-3p

0.21717685032195

3.01801547172665e-06

mmu-miR-382-5p

–0.685715007941653

3.64738428587348e-06

mmu-miR-296-3p

–2.50433089112428

4.13196392781144e-06

mmu-miR-383-3p

–4.36682736737434

5.99751181436721e-06

mmu-miR-758-3p

–0.742538546447116

7.44436572001326e-06

mmu-miR-741-5p

–0.727327582643753

7.88635516720674e-06

mmu-miR-471-5p

–0.473611708662899

9.08215926529089e-06

mmu-miR-124-3p

–0.343137261329243

1.14006775093623e-05

mmu-miR-1981-5p

–0.915616255542013

1.26283854908024e-05

mmu-miR-148b-3p

–0.209675429221931

1.71023039746911e-05

mmu-let-7c-5p

0.0230611386572123

2.32588758897331e-05

mmu-miR-29b-3p

–0.386279730040515

2.40809984569191e-05

mmu-miR-181a-1-3p

0.117621002104981

2.47049260488566e-05

mmu-miR-350-5p

–0.426205914453275

2.47712318330638e-05

mmu-miR-873a-5p

–1.11361202257099

2.59679075765097e-05

mmu-miR-205-5p

4.12502572895533

3.11790271079374e-05

mmu-miR-200b-5p

–5.04489927248698

3.20007791126184e-05

mmu-miR-883b-3p

–0.461167215372084

3.20035883196802e-05

mmu-miR-222-3p

–0.303875461746418

3.22587650434279e-05

mmu-miR-494-3p

–0.506552131040954

3.59587401356126e-05

mmu-miR-451a

0.692066321679227

3.8669103264584e-05

mmu-miR-1191

–0.988315744120612

3.89344819762453e-05

mmu-miR-29c-3p

–0.217787539648586

5.27311667099141e-05

mmu-miR-3057-3p

–2.62986177320814

5.46151704515601e-05

mmu-miR-1839-3p

–1.46939710101489

5.85854108727316e-05

mmu-miR-8103

0.916626579698385

6.14705745790221e-05

mmu-miR-6540-3p

–2.26729169382343

6.30678698672979e-05

mmu-miR-340-3p

–0.1851355826357

7.21946885655249e-05
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mmu-miR-194-5p

–0.329749263575639

8.44564172828964e-05

mmu-miR-7679-5p

1.00346374907442

9.13174387633848e-05

mmu-miR-15a-3p

–1.12736143267895

0.000101532892202008

mmu-miR-384-5p

–0.433112983690112

0.000126404496301453

mmu-miR-142-5p

–0.669754500331649

0.000154222257577804

mmu-miR-30c-1-3p

–0.275031954040219

0.000172168658842951

mmu-miR-145a-3p

–3.13236211373732

0.000209334158458209

mmu-miR-742-5p

–1.16828168799226

0.000232005387391383

mmu-miR-7015-3p

0.665594110318035

0.000241198748965684

mmu-miR-146b-5p

–0.119353698124996

0.000252011400236973

mmu-miR-494-5p

–0.413643119491887

0.000263563490600416

mmu-miR-330-5p

–0.353309043199648

0.000331673530564297

mmu-miR-615-3p

–4.62986177320814

0.000382675581585344

mmu-miR-329-3p

–0.749892476914906

0.000387319815339233

mmu-miR-30c-2-3p

–0.134207785737928

0.000404185530480204

mmu-miR-455-5p

–0.354227330594709

0.000441085455532589

mmu-miR-350-3p

–0.786366258888126

0.000454323185739873

mmu-miR-6989-3p

–3.74533899062807

0.000490501477238876

mmu-miR-155-5p

4.54006322823418

0.000496080688496162

mmu-miR-676-5p

–0.57359355356139

0.000665573125754333

mmu-miR-301a-5p

–0.447747362757909

0.000688612809507308

